• Help people with EB

    Your support of DEBRA International or a national EB group enables us to provide the best quality of life for families and individuals affected by EB.

Donation Account: IBAN AT65 6000 0005 1004 5254, BIC BAWAATWW, DEBRA International, Am Heumarkt 27/1, 1030 Vienna

donate now
Composite of 6 images. (1) Family with a child with EB sitting on the woman's lap; (2) male EB patient getting a dental treatment; (3) Wounded face of a baby girl with EB; (4) Fingers with blisters and wounds; (5) Hand and lower arm of an EB patient; (6) People in a meeting room

04.07.2014

A focus on the Centre for Human Genetics, Bangalore, India

Dr Ravi Hiremagalore reports his experience of establishing a multi-disciplinary clinic and services available for the care of EB patients in Bangalore, India[more]

Conference room, Powerpoint presentation and John Dart as a speaker on the podium

27.05.2014

A spotlight on rare diseases for three days in Berlin

The EURORDIS membership meeting and the European Conference on Rare Diseases (ECRD) were held back-to-back in Berlin, and EB was well represented[more]

2 images; left: Arabella von Gelmini-Kreutzhof (ambassador of DEBRA South Tyrol), holding a butterfly statuette, and Isolde Mayr faccin, president of DEBRA South Tyrol, presenting a document // right: close-up of  butterfly trophies from DEBRA CR

30.04.2014

Two anniversaries - one mission

Both DEBRA Czech Republic and DEBRA South Tyrol celebrated their 10-year anniversaries this month. We warmly congratulate them![more]

Jury meeting in a conference room

03.04.2014

DEBRA supporting research: an update

For our current call for EB research proposals, an exceptionally high 18 applications have been received. In parallel, planning for our next research conference is underway.[more]

Chalkboard with "Stamina?" written on it

02.04.2014

Unproven cell therapy from the Stamina Foundation in Italy now being re-evaluated

Leading stem-cell experts raised strong concerns about a treatment by the Stamina Foundation in Italy. It must now prove safety in a clinical trial.[more]